BNR Stock: Burning Rock Biotech Limited Stock Price, Analysis & Insights
Get live bnr stock price $14.06, comprehensive Burning Rock Biotech Limited stock analysis, charts, news, and expert forecast. Real-time bnr stock data and investment insights.
Loading chart...
Company Overview
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Company Information
- CEO
- Yusheng Han
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 674
Contact Information
- Website
- https://www.brbiotech.com
- Address
- No. 5, Xingdao Ring Road North
- Country
- CN
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.27)
Business Model & Strategy
Burning Rock Biotech Limited operates in the Medical - Diagnostics & Research industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Yusheng Han, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Diagnostics & Research model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Burning Rock Biotech Limited competes in the Medical - Diagnostics & Research within the broader Healthcare. With 15.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Burning Rock Biotech Limited provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Burning Rock Biotech Limited should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Burning Rock Biotech Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Burning Rock Biotech Limited
- ⚠Investors should consider how Burning Rock Biotech Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
15.14M
P/E Ratio
-7.40
Beta
1.27
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 15.14M market capitalization
- Trading Volume: 5.83K shares traded today
- Price Range: 52-week range of $2.18 - $16.28
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Burning Rock Biotech Limited
Burning Rock Biotech Limited (BNR) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. With a current market capitalization of 15.14M, the company represents a significant player in its market. The stock is currently trading at $14.06 with a negativedaily change of 7.98%.
The company's 674 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -7.40, beta of 1.27, and 52-week price range from $2.18 to $16.28when evaluating investment opportunities.
Why Invest in Burning Rock Biotech Limited?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Yusheng Han
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.